2020
S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien H, Herrin J, Dulai P, Sangaralingham L, Shah N, Sandborn W. S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. The American Journal Of Gastroenterology 2020, 115: s444-s445. DOI: 10.14309/01.ajg.0000705492.87799.ce.Peer-Reviewed Original Research
2015
Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods
Feinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs 2015, 34: 592-600. PMID: 25847641, DOI: 10.1377/hlthaff.2014.1119.Peer-Reviewed Original ResearchConceptsStage II diseaseStage III diseaseCancer-related costsCancer careBreast cancerMedian costSurvival rateEnd Results Program-MedicareFive-year survivalCancer care costsBreast surgerySurvival outcomesImproved outcomesOlder womenRadiation therapyCare costsStage IIDiseaseStudy periodWomenCancerCareSignificant national attentionOutcomesPercent